



Ocular Therapeutix™ Strengthens Management Team with the Appointment of Andy Hurley as Chief Commercial Officer

October 20, 2016

BEDFORD, Mass--(BUSINESS WIRE)--Oct. 20, 2016-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Andy Hurley to the newly created position of chief commercial officer, effective immediately. In this role, Mr. Hurley will be responsible for leading Ocular's commercial organization, focusing on effective execution of potential future product launches, brand development, and ongoing commercialization strategies.

"Andy brings extensive commercial strategy and product launch expertise as well as a proven ability to develop and lead commercialization efforts globally," said Amar Sawhney, Ph.D., President, Chief Executive Officer and Chairman of Ocular Therapeutix. "Andy's experience will be extremely valuable as we continue to prepare for the potential launch of our lead product candidate, DEXTENZA™, where our objective is to maximize product uptake and revenue from the outset. If approved by the FDA, we believe DEXTENZA would be the first extended release steroid containing no preservatives available to ophthalmologists that would provide the complete course of therapy with a single placement."

Mr. Hurley has over two decades of sales, marketing, market access and commercial operations experience across the pharmaceutical industry. Most recently, Mr. Hurley served as Vice President, Sales and Marketing at Dyax Corporation prior to its acquisition by Shire in January 2016. In this role, Mr. Hurley led the strategic and tactical launch planning for the launch of DX-2930, a product candidate under development for the treatment of hereditary angioedema, or HAE. Prior to Dyax, Mr. Hurley held several senior positions within Sunovion Pharmaceuticals, including Vice President of Marketing and Vice President of Commercial Operations. At Sunovion, he was responsible for leading all marketing activities for its asthma franchise, including overall strategic planning, life cycle strategy, advertising campaigns, and market research. He also led commercial operations functions including sales training, relationship marketing and sales operations. Earlier in his career, Mr. Hurley held commercial operations and sales roles at NitroMed and Forest Pharmaceuticals. Mr. Hurley has also held various consulting roles, providing commercial strategy development and tactical support to the biotech industry.

"I am excited to join Ocular Therapeutix at such an important juncture for the Company as it prepares for the potential commercialization of DEXTENZA," stated Mr. Hurley. "I look forward to working with the world class team at Ocular to launch and commercialize DEXTENZA as well as the Company's additional innovative, extended release product candidates across diverse indications in ophthalmology."

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix has submitted an NDA for post-surgical pain for its lead product candidate, DEXTENZA™ (dexamethasone insert, extended release), which is in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and in Phase 2 clinical development for dry eye disease. OTX-TP (sustained release travoprost) is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating sustained-release injectable drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery. For additional information about the Company, please visit www.ocutx.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company including the development and regulatory status of the Company's product candidates, such as the Company's expectations and plans regarding regulatory submissions for and the timing and conduct of clinical trials of DEXTENZA™ for post-surgical ocular inflammation and pain, including our expectations regarding the NDA filed with the FDA, DEXTENZA for the treatment of allergic conjunctivitis, DEXTENZA for dry eye disease and OTX-TP for the treatment of glaucoma and ocular hypertension, the potential utility of any of the Company's product candidates, potential commercialization of the Company's product candidates, the sufficiency of the Company's cash resources and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "goal," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the timing and costs involved in commercializing ReSure® Sealant or any product candidate that receives regulatory approval, the initiation and conduct of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company's scientific approach and general development progress, the availability or commercial potential of the Company's product candidates, the sufficiency of cash resources and need for additional financing or other actions and other factors discussed in the "Risk Factors" section contained in the Company's quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.

Source: Ocular Therapeutix, Inc.

Investors

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

bsmith@ocutx.com

or

Burns McClellan on behalf of Ocular Therapeutix

Steve Klass, 212-213-0006

sklass@burnsmc.com

or

Media

Ocular Therapeutix, Inc.

Scott Corning

Vice President of Sales and Marketing

scorning@ocutx.com